GLP-1 Drugs Counter Aging Across the Entire Body in Mice
A landmark multi-omic study shows GLP-1 receptor agonists like semaglutide broadly reverse age-related molecular changes in aging mice.
Summary
Researchers at The Chinese University of Hong Kong used deep molecular profiling to show that GLP-1 receptor agonists (GLP-1RAs) — the drug class behind semaglutide and liraglutide — produce sweeping, body-wide anti-aging effects in male aging mice. Treated mice showed reversal of age-related molecular changes across multiple tissues and improved physical function. Crucially, these effects were specific to older animals and achieved at low doses that barely affected food intake or weight. When treatment began in very old mice, effects were even stronger and linked to hypothalamic GLP-1 receptor signaling, suggesting a brain-body aging axis. The molecular profile of GLP-1RA treatment closely resembled that of rapamycin, a gold-standard longevity intervention.
Detailed Summary
As the global population ages, identifying safe and practical interventions to slow or reverse age-related decline has become a major research priority. GLP-1 receptor agonists, already widely used for diabetes and obesity, have shown unexpectedly broad health benefits — but the mechanisms behind these pleiotropic effects remain poorly understood. This study offers a comprehensive multi-omic explanation.
Researchers treated aging male mice with a GLP-1RA starting at 11 months of age for 30 weeks, then performed deep molecular profiling across multiple tissues alongside functional assessments. The results revealed strong, body-wide counteraction of age-related molecular changes — spanning genomic, transcriptomic, proteomic, and metabolomic layers — along with improvements in selected physical performance measures.
A critical finding was the age-specificity of the effects: young adult mice showed minimal response to the same treatment, suggesting GLP-1RAs engage aging-specific biological pathways rather than broadly suppressing metabolism. Equally important, the benefits were achieved at relatively low doses that minimally altered food intake or body weight, dissociating the anti-aging effects from appetite suppression.
When treatment began later — at 18 months for 13 weeks — the anti-aging molecular signature was even more pronounced. These effects were largely dependent on hypothalamic GLP-1 receptor signaling, pointing to a brain-body axis as a central mechanism of systemic aging modulation. This finding opens exciting new avenues for understanding how the brain coordinates whole-body aging.
Strikingly, multi-omic comparison with rapamycin (mTOR inhibition), one of the most validated longevity interventions in preclinical research, revealed strong molecular similarities. This positions GLP-1RAs as a potentially accessible, clinically available class of anti-aging therapeutics. Caveats include the exclusively male mouse model, limited translatability data, and the absence of lifespan endpoints.
Key Findings
- GLP-1RA treatment produced body-wide multi-omic reversal of age-related molecular changes in aging male mice.
- Anti-aging effects were age-specific, with minimal impact observed in young adult mice at the same dose.
- Benefits occurred at low doses with little effect on food intake or body weight, separating anti-aging from appetite mechanisms.
- Late-life treatment (18 months) showed even stronger effects, largely dependent on hypothalamic GLP-1R signaling.
- Multi-omic profile of GLP-1RA treatment closely resembled rapamycin, a gold-standard longevity intervention.
Methodology
The study used aging male mice treated with a GLP-1RA starting at 11 or 18 months of age for 30 or 13 weeks respectively. Deep multi-omic molecular profiling (genomic, transcriptomic, proteomic, metabolomic) was performed across multiple tissues alongside functional physical assessments. Comparisons were made with rapamycin-treated mice and with young adult controls.
Study Limitations
The study was conducted exclusively in male mice, limiting generalizability to females and humans. No lifespan or healthspan endpoint data were reported, so it remains unknown whether molecular changes translate to longer or healthier lives. Translational relevance to human aging biology requires validation in clinical studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.